The Australian government on Thursday changed its CCP virus immunisation advice to recommend that AstraZeneca only be recommended for people aged 60 and over. This comes after experts found new evidence to suggest that there is a much higher risk of a rare but serious blood clot condition known as thrombosis and thrombocytopenia syndrome (TTS) in the 50-59 age group. As a result, only the Pfizer vaccination is to be recommended for those aged 59 and under. The Australian Technical Advisory Group on Immunisation (ATAGI) continues to recommend that AstraZeneca be used for people aged 60 and over based on the higher risk of illness and death from COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. There is also a lower risk of the TTS condition in that age group. Between April and June 16, there have been 60 cases of confirmed TTS in Australia, with two deaths. Health Minister …